Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lymphoma, B-Cell × Rituximab × Clear all

Phase

Phase 2 35 Phase 1 23 Phase 1/2 15 Phase 3 10 Phase EARLY_PHASE1 2 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 5 Lymphoma, Non-Hodgkin 4 Lymphoma, Follicular 3 Lymphoma 3 Waldenstrom Macroglobulinemia 1 Recurrence 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Leukemia 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00147121 2016-09-22

Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)

Japan Clinical Oncology Group

Phase 2/3 Completed

Lymphoma, Follicular, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡